This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
DAIC
MAY 6, 2024
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
The British Journal of Cardiology
JANUARY 14, 2025
Seventy-nine responses describing hospital-based HF services from all devolved countries were received. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF. Just over half of HF hospital services had a one-stop diagnostic clinic with a median of two clinics per week. and 75%, respectively.
Medical Xpress - Cardiology
JULY 29, 2024
A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
JAMA Cardiology
NOVEMBER 17, 2024
This cohort study evaluated adoption rates of sodium-glucose cotransporter-2 inhibitors at US hospitals for patients with heart failure and mildly reduced or preserved left ventribular ejection fraction.
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 
DAIC
JUNE 4, 2024
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10. Tenax Therapeutics Announces New U.S.
Circulation
JANUARY 22, 2025
Circulation, Ahead of Print. Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.
European Journal of Heart Failure
OCTOBER 30, 2023
In patients with heart failure with preserved ejection fraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejection fraction (LVEF). After a median follow-up of 4.6 years,
Circulation
NOVEMBER 11, 2024
As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Multivariate logistic and linear regression analyses were performed, adjusting for multiple patient and hospital confounders.
Journal of Cardiovascular Electrophysiology
DECEMBER 17, 2024
Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. HFpEF were defined as HFA-PEFF score of 5 or 6 and left ventricular ejection fraction 50% before the initial CA. 423 by a log-rank test).
European Journal of Heart Failure
NOVEMBER 29, 2023
Methods Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries.
Journal of Cardiovascular Electrophysiology
FEBRUARY 13, 2024
Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Aggregate data comparing the risk profile of AF between these three HF categories are lacking.
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide. Cox regression was used to study the effect of empagliflozin on incident LRTI.
DAIC
JUNE 21, 2024
The investigators concluded that INPEFA is a cost-effective addition to standard of care for patients hospitalized with heart failure and comorbid diabetes. According to the research results, the use of INPEFA led to a net gain in QALYs of 0.425 for INPEFA versus standard of care. healthcare system,” said Craig Granowitz, M.D.,
105 HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.
HeartRhythm
APRIL 30, 2024
Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).
HeartRhythm
JUNE 23, 2024
Furthermore, among patients with heart failure, both reduced and preserved ejection fraction, catheter ablation reduces heart failure hospitalizations and mortality.1-10
JAMA Cardiology
SEPTEMBER 30, 2021
This cohort study examines the prevalence of epicardial coronary artery disease and coronary microvascular dysfunction in hospitalized patients with heart failure with preserved ejection fraction.
Journal of the American Heart Association
JANUARY 19, 2024
BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. The study outcome was time to the first hospitalization for HF. In 10 019 middle‐aged individuals (mean age, 63.3±10.6
JAMA Cardiology
JULY 23, 2024
Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.
Frontiers in Cardiovascular Medicine
OCTOBER 10, 2024
MethodsFrom December 1, 2022 to February 1, 2024, 103 patients with heart failure were consecutively enrolled from the cardiology clinic or ward of the First Affiliated Hospital of Nanjing Medical University. Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.
Circulation
NOVEMBER 11, 2024
Left ventricular ejection fractions were similar in both MAC (58.3 + 11.9) Conclusion:Among patients hospitalized with ‘diastolic heart failure’ MAC is associated with worse cardiovascular outcomes. Conclusion:Among patients hospitalized with ‘diastolic heart failure’ MAC is associated with worse cardiovascular outcomes.
European Journal of Heart Failure
MARCH 30, 2025
We assessed the associations of MetS indices with echocardiographic parameters, biomarkers of myocardial damage (high-sensitivity cardiac troponin I [hs-cTnI] and B-type natriuretic peptide [BNP]) and incident HF hospitalizations including HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).
DAIC
JANUARY 23, 2024
To date, no clinically relevant changes in serum sodium levels or progressive hyponatremia were observed and none of the patients needed to be hospitalized for congestion since the start of the study. At the start of the study treatment period, loop diuretics were withheld, and patients were treated with DSR 2.0
104 
European Journal of Heart Failure
FEBRUARY 5, 2025
This effect was more pronounced in patients with HF with reduced ejection fraction ( p interaction <0.0001). Patients treated with ARNI had a lower risk of all-cause mortality (risk ratio [RR] 0.64; 95% CI 0.450.92; p =0.01) but had a similar rate of HF hospitalization (RR 0.71; 95% CI 0.431.18; p =0.19).
DAIC
MARCH 26, 2025
live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 4 Approximately 6.7 million adults in the U.S. Bozkurt A, et al.
Journal of the American Heart Association
DECEMBER 14, 2024
The main outcome was the composite of allcause mortality and first HF hospitalization. The mean age, body mass index, left ventricular ejection fraction, and EAT volume were 57.0 During a median followup of 34 months, 169 patients (24.4%) died or were hospitalized for HF. Of 692 participants, 41.3% were women.
Frontiers in Cardiovascular Medicine
FEBRUARY 6, 2025
This study aimed to evaluate the association between PWR and all-cause mortality within 30 days of hospitalization in ADHF patients from Jiangxi, China.MethodsA total of 1,453 ADHF patients from the Jiangxi-ADHF study1 cohort were included. The primary outcome measure was all-cause mortality within 30 days of hospitalization.
European Journal of Heart Failure
DECEMBER 13, 2023
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.
Science Daily - Heart Disease
SEPTEMBER 2, 2024
Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.
European Journal of Heart Failure
DECEMBER 19, 2024
BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.
European Journal of Heart Failure
DECEMBER 7, 2023
ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). Individuals with biatrial myopathy had an 84% higher risk of HF hospitalization or death as compared to those with isolated LA myopathy (HR 1.84; 95% CI, 1.16–2.92,
Journal of Cardiovascular Electrophysiology
OCTOBER 21, 2024
Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). The primary endpoint was a composite of death from any cause or hospitalization for worsening HF.
European Journal of Heart Failure
DECEMBER 15, 2024
A summary of effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death. All participants in PARAGON-HF were divided into three age groups: <65years, 6574years, and75years.
European Journal of Heart Failure
FEBRUARY 18, 2024
Global longitudinal strain (GLS) and clinical outcomes in heart failure with preserved ejection fraction (HFpEF). Almost 47% of patients with HFpEF had evidence of left ventricular (LV) subclinical dysfunction, defined as absolute LV GLS 0.1).
European Journal of Heart Failure
FEBRUARY 5, 2025
Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).
DAIC
FEBRUARY 22, 2024
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.
105 
European Journal of Heart Failure
NOVEMBER 3, 2024
The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known. Methods CABA-HFPEF-DZHK27 (NCT05508256) is an investigator-initiated, prospective, randomized, open, interventional multicentre strategy trial with blinded outcome assessment.
European Journal of Heart Failure
OCTOBER 5, 2023
Abstract Aims Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. Altogether, 5874 patients (34.6%) received a CCB (87.6%
Journal of the American Heart Association
FEBRUARY 19, 2025
A secondary hierarchical outcome consisted of cardiovascular death, HF hospitalizations, urgent HF visits, and NTproBNP change. The primary end point was timeaveraged proportional change in NTproBNP (Nterminal proBtype natriuretic peptide) from baseline through weeks 4 and 8.
Science Daily - Heart Disease
MARCH 26, 2025
Compared with those who spent most of their time in a single room, people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a new study.
European Journal of Heart Failure
OCTOBER 9, 2023
Impact of COVID-19 in patients with HF and mildly reduced and preserved ejection fraction. Methods and results Participants with chronic heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) were randomized to dapagliflozin or placebo across 350 sites in 20 countries. versus 6.4 (95%
DAIC
MARCH 29, 2024
"We're pleased to present the RELIEVE-HF data at this year's ACC meeting, as we continue to advance this important technology with the goal of bringing a much-needed treatment option to patients with advanced heart failure, a leading cause of death and hospitalization in the U.S. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.
Circulation
NOVEMBER 11, 2024
Background:Left ventricular global longitudinal strain (GLS) has been associated with mortality and heart failure hospitalization (HFH) among subjects with chronic heart failure, but not in patients with acute decompensated heart failure (ADHF).
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content